Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Jiangsu Hengrui Pharmaceuticals
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
9.5%
+3.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:VulnerableThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
BeiGene
Competitor Displacement Rate
12.5%
Competitors are displacing Jiangsu Hengrui Pharmaceuticals in 12.5% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Competitors are demonstrating faster clinical trial progression and approvals for novel oncology drugs, particularly in China, which is a key market for Hengrui.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[chinadrugreview.org][nhc.gov.cn]⚠️ Identified Vulnerability:Clinical Trial Speed
Primary Threat Identified:BeiGene
Target Persona:Oncologists in Emerging Markets
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)